Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03842358 · ClinicalTrials.gov registry record · NA

Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography

A NA study, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
298
Enrollment target

NCT03842358: Completed NA study, sponsored by Washington University School of Medicine.

NCT03842358 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 298 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03842358, a NA study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
298 participants
Enrollment target

Study Summary

Ultrasound-guided diffuse optical tomography (DOT) has demonstrated its potential role in differentiating malignant and benign breast abnormalities and in predicting and monitoring the neoadjuvant chemotherapy (NAC) response of breast cancer. This unique approach employs a commercial ultrasound (US) transducer and near infrared (NIR) optical imaging sensors mounted on a hand-held US probe. The co-registered US is used for lesion localization, and optical sensors are used for imaging tumor related vascularity.

Primary Outcome

-BI-RADS scores without and then with optical data will be rendered by study radiologists. Radiologists will be blinded to the biopsy exam and pathology outcomes. Optical data including total Hemoglobin concentration will be provided by the bioengineering team. Benign biopsy reduction will be calculated as the proportion of reads (CI \& US-DOT subtract CI) with a non- suspicious assessment, i.e. BIRADS 2 'benign' or BIRADS 3 'probably benign', divided by the denominator of total reads with no ca

Interventions

  • DEVICE Hand-held hybrid probe

Trial Details

FieldValue
Enrollment Target 298 participants
Start Date 2019-03-05
Est. Completion 2024-07-30
Phase NA

What the finished NCT03842358 record still lists

NCT03842358 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 1 intervention - of which Hand-held hybrid probe is the first listed.

NCT03842358 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03842358 about?

NCT03842358 is a clinical study titled "Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography". Ultrasound-guided diffuse optical tomography (DOT) has demonstrated its potential role in differentiating malignant and benign breast abnormalities and in predicting and monitoring the neoadjuvant chemotherapy (NAC) response of breast cancer. This unique approach employs a commercial ultrasound (US)...

What is the current status of trial NCT03842358?

This trial is currently completed. It is a NA study. The enrollment target is 298 participants. The study started on 2019-03-05. Estimated completion is 2024-07-30.

What interventions are being tested in trial NCT03842358?

The interventions under investigation include: Hand-held hybrid probe (DEVICE).

Who is sponsoring clinical trial NCT03842358?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03842358's enrollment target sits among peer trials

298 371st of 2000 higher than 1,629 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06305624 · 298 participants · NA

    Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

  • NCT06754215 · 298 participants · NA

    Smoking Cessation Intervention Development for Homeless Youth

  • NCT06780111 · 298 participants · Phase 1

    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  • NCT07209358 · 298 participants · NA

    EDX110 Randomized Control Trial for Treatment of DFUs

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03842358, the US trial registry maintained by the National Library of Medicine. NCT03842358 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.